News

Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and professor Timothy Springer. The proceeds of this financing will be used to expand Selecta’s R&D

Synexus through its network of wholly owned sites staffed by full time good clinical practice trained investigators is able to carry out the whole of a Phase II

The marketing application submitted to the Australian regulatory authorities included safety and efficacy data from three multi-national clinical studies: Triumph, a placebo-controlled 26-week Phase III study involving 87

Dr Scarlett brings nearly 30 years of experience in drug development and commercialization to his new role. Susan Molineaux, who founded Proteolix in 2003, will transition from her

As part of the agreement, Sigma-Tau will make a $6 million upfront investment in Dor, inclusive of the $1.5 million which was recently completed under a letter of

The program consists of three randomized, double-blind, placebo-controlled Phase III clinical studies with Cerimon’s diclofenac patch. The studies will assess the efficacy and safety of Cerimon’s diclofenac patch

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of

“Our progress toward commercializing our products, and building and expanding our quality customer base, continue on target,” said William Moffitt, Nanosphere’s president and chief executive officer. “In January

“Over the last while we have faced significant challenges and, with the current economic environment, we are not currently able to continue to finance our clinical or operational